another country4 was logical, provided we allowed for ethnic and age differences in mortality (by excluding non-caucasians and confining the comparison to 15-64 year olds as studied in England). The interval between the two studies is unlikely to have altered the comparison materially, as the increase in mortality in New Zealand had occurred before 1979, when the study was conducted in England, and continued through 1981-3, when the New Zealand study was conducted. The "single radical difference" in therapeutic policy between the two studies-the use of bronchodilator nebulisers at home-contributed only slightly to New Zealand mortality. Delay due to overreliance on a home nebuliser was a factor in, at most, 8% of fatal cases. Underuse of corticosteroids and failure of patients and doctors to appreciate the severity of the fatal attack were seen in patients with nebulisers as commonly as in those without. The study that Dr Grant suggests, comparing death rates in all patients given nebulisers with that in a group of controls, is indeed formidable and may be impossible, particularly with respect to obtaining -matched controls.
The accuracy of death certification in 15-64 year olds is of concern when comparing official mortality statistics, although we found that the net false positive rate in New Zealand caucasians in this' age group was lower than that in England.4 In our paper, however, we used mortality rates determined in each country for persons of the same race and the same age group, and for whom a panel of experienced respiratory physicians in each country concluded, after reviewing all the evidence, that the subjects had died of asthma. The difference in this "verified" asthma mortality of 4-20 per 100 000 in New Zealand and 1-84 per 100 000 in England therefore is not explained even in part by diagnostic error.
Some of Dr Grant's assumptions are not entirely accurate. The proportion of non-caucasian deaths from asthma in 5-34 year olds has not remained at 48%, as in the two year study period. Their death rate has fallen more dramatically than the rate in noncaucasians and in 1985 accounted for only 16% of deaths from asthma in this age group. The mortality in 5-34 year old caucasians (1-7 per 100000 in 1985) remains twice that in England and four to five times that in the United States, Canada, and most European countries in this age group. The second conclusion is likewise not substantiated. In the 1981-3 study only 36% of the"excess" mortality in New Zealand was explained by higher mortality rates in non-caucasians, who constitute only 8-8% of the total New Zealand population and 10-9% of the 5-34 year old population, not 15% as used by Dr Grant in his calculations.
The third conclusion, that the introduction of new forms of drug treatment affected mortality, cannot be proved or disproved on available evidence. We believe that inappropriate treatment, combined with delays in seeking and providing medical help, were the most common contributory factors to fatal asthma. Nevertheless, in the face of greater use of all forms of antiasthma treatments in New Zealand than in Australia or England5 and the higher rate of "unavoidable" deaths in New Zealand, the possibility that asthma in New Zealand has increased in severity cannot be discounted. The current downward trend in New Zealand mortality may reflect an even more aggressive approach to pharmacological management of severe asthma.
It is too soon to be confident that the second epidemic has subsided. Furthermore, even if asthma mortality among New Zealand caucasians has fallen to the same level found in England and Wales that still is unacceptable, as the British Thoracic Association determined-that 86% of all deaths it investigated were avoidable.4 New Zealand caucasians aged 5-34 years continue to die from asthma at twice the rate of their counterparts in England and Wales. To assume that the second New Zealand "epidemic" was a rerun of the 1960s epidemic, and to ignore the possibility that asthma may be increasing in severity, would be unwise. Lessons can be learnt from past and present studies, and perhaps by prospective studies in view of current trends towards rising mortality in the United States, Canada, England, and some other countries.
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